Evolus : Scientific Investor Presentation

Published: 2025-05-15 12:41:10 ET EOLS

Published on 05/15/2025 at 12:41

MAY 2025

Proven Performance with proven safety in 5 clinical studies and the largest head-to-head study against BOTOX cosmetics

Designed for Precise outcomes that result in high patient satisfaction

Unique HI-PURE Manufacturing that contributes to the efficacy and safety backed up by science

Made with Cold-X technology which uses

near-freezing temperatures designed to preserve

the natural structure of the HA molecule

Demonstrates non-inferiority & statistical superiority at 6 months vs. Restylane-L in a pivotal trial*

Recognizes weight loss in the patient label

as a factor in wrinkle formation

*In the US pivotal trial, based on blinded live evaluator assessments using the WSRS, Evolysse FormTM demonstrated statistical significance vs. control at all time-points through 12 months, and Evolysse SmoothTM demonstrated statistical significance vs. control at months 6 and 9(p<0.05) 3

EVOLYSSE , AN INNOVATIVE TECHNOLOGY THAT COMPLEMENTS THE JEUVEAU® BRAND

4

25+ YEARS IN R&D AND MANUFACTURING OF AESTHETICS & MEDICAL BIOMATERIALS

LAUNCHED FIRST 2 PRODUCTS: HEMOTESE® & COLLAPAT®II

PEROUSE PLASTIE BREAST IMPLANTS SOLD TO MENTOR

LAUNCH OF NEVELIA®, DERMAL REGENERATION MATRIX

1997

2003

2004

2007

2011

2013

2021

SYMATESE FOUNDED BY INDUSTRY EXPERTS

ENTERED PARTNERSHIP WITH L'ORÉAL

SOLD RIGHTS OF XpresHAn TECHNOLOGY /OBT® AND RELATED DERMAL FILLERS TO GALDERMA

R&D PARTNERSHIP STRENGTHENED WITH L'ORÉAL ON BIOMATERIALS

5

Disclaimer

Evolus Inc. published this content on May 13, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 15, 2025 at 16:40 UTC.